{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:32:28Z","timestamp":1795026748912,"version":"4.10.2"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007680","name":"Naval Medical Research Command","doi-asserted-by":"publisher","award":["MOH-000248\\u201300"],"award-info":[{"award-number":["MOH-000248\\u201300"]}],"id":[{"id":"10.13039\/100007680","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","award":["SD GMC ( DDC\/FY2023\/EX\/79-A117"],"award-info":[{"award-number":["SD GMC ( DDC\/FY2023\/EX\/79-A117"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","award":["H23G1a0009"],"award-info":[{"award-number":["H23G1a0009"]}],"id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004071","name":"Khon Kaen University","doi-asserted-by":"publisher","award":["NSRF"],"award-info":[{"award-number":["NSRF"]}],"id":[{"id":"10.13039\/501100004071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003081","name":"Ministry of Education, Ethiopia","doi-asserted-by":"publisher","award":["FY2024-MOET1\\u20130002"],"award-info":[{"award-number":["FY2024-MOET1\\u20130002"]}],"id":[{"id":"10.13039\/501100003081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["236B9008"],"award-info":[{"award-number":["236B9008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118273","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T23:37:00Z","timestamp":1750030620000},"page":"118273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Synergistic suppression of cholangiocarcinoma cells via DNA damage response and cell cycle arrest by dual targeting PARP and ATM in DNA damage repair pathway"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7634-3729","authenticated-orcid":false,"given":"Rattanaporn","family":"Jaidee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piman","family":"Pocasap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-7771","authenticated-orcid":false,"given":"Apinya","family":"Jusakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laddawan","family":"Senggunprai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auemduan","family":"Prawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Han","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Lee","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerapol","family":"Kukongviriyapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin Tean","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarinya","family":"Kongpetch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.biopha.2025.118273_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118273_bib2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/gutjnl-2011-301748","article-title":"Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update","volume":"61","author":"Khan","year":"2012","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.biopha.2025.118273_bib3","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.biopha.2025.118273_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100737","article-title":"Clinical treatment of cholangiocarcinoma: an updated comprehensive review","volume":"27","author":"Elvevi","year":"2022","journal-title":"Ann. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118273_bib5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrc1296","article-title":"Targeting the checkpoint kinases: chemosensitization versus chemoprotection","volume":"4","author":"Zhou","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2025.118273_bib6","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.annonc.2021.04.012","article-title":"Practical considerations in screening for genetic alterations in cholangiocarcinoma","volume":"32","author":"Bekaii-Saab","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118273_bib7","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-022-30708-7","article-title":"The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2025.118273_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.37349\/etat.2022.00079","article-title":"Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy","volume":"3","author":"Carotenuto","year":"2022","journal-title":"Explor Target Antitumor Ther."},{"issue":"15","key":"10.1016\/j.biopha.2025.118273_bib9","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1158\/1078-0432.CCR-19-0127","article-title":"Alterations in DNA damage repair genes in primary liver cancer","volume":"25","author":"Lin","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2025.118273_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/medicines7090054","article-title":"PARP inhibitors in biliary tract cancer: a new kid on the block?","volume":"7","author":"Ricci","year":"2020","journal-title":"Medicines"},{"issue":"8","key":"10.1016\/j.biopha.2025.118273_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/genes10080565","article-title":"PARP inhibitors in prostate cancer-the preclinical rationale and current clinical development","volume":"10","author":"Virtanen","year":"2019","journal-title":"Genes"},{"issue":"9","key":"10.1016\/j.biopha.2025.118273_bib12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","article-title":"Synthetic lethal therapies for cancer: what's next after PARP inhibitors?","volume":"15","author":"Ashworth","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118273_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O'Neil","year":"2017","journal-title":"Nat. Rev. Genet"},{"issue":"2","key":"10.1016\/j.biopha.2025.118273_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pilie","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118273_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","article-title":"An overview of PARP inhibitors for the treatment of breast cancer","volume":"16","author":"Cortesi","year":"2021","journal-title":"Target Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118273_bib16","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1111\/jcmm.14133","article-title":"PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms","volume":"23","author":"Jiang","year":"2019","journal-title":"J. Cell Mol. Med"},{"issue":"6","key":"10.1016\/j.biopha.2025.118273_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061416","article-title":"PARP inhibitors: a new horizon for patients with prostate cancer","volume":"10","author":"Congregado","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.biopha.2025.118273_bib18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/gutjnl-2019-319970","article-title":"Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer","volume":"70","author":"Gout","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.biopha.2025.118273_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2025.118273_bib20","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.2741\/4866","article-title":"Evolution of PIKK family kinase inhibitors: a new age cancer therapeutics","volume":"25","author":"Shaik","year":"2020","journal-title":"Front Biosci. (Landmark Ed. )"},{"key":"10.1016\/j.biopha.2025.118273_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102808","article-title":"Targeting the ATM pathway in cancer: opportunities, challenges and personalized therapeutic strategies","volume":"129","author":"Lee","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2025.118273_bib22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tranon.2017.01.007","article-title":"ATM-deficient colorectal cancer cells are sensitive to the PARP inhibitor olaparib","volume":"10","author":"Wang","year":"2017","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.biopha.2025.118273_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1380633","article-title":"PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1\/2 and RAD51 downregulation","volume":"14","author":"Muvaffak","year":"2024","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118273_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","article-title":"Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically","volume":"19","author":"Riches","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.biopha.2025.118273_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e31112","article-title":"Dual blockage of PI3K-mTOR and FGFR induced autophagic cell death in cholangiocarcinoma cells","volume":"10","author":"Mahaamnad","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.biopha.2025.118273_bib26","doi-asserted-by":"crossref","first-page":"8621","DOI":"10.1038\/s41598-025-93192-1","article-title":"Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization","volume":"15","author":"Jaidee","year":"2025","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.118273_bib27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinforma."},{"issue":"1","key":"10.1016\/j.biopha.2025.118273_bib28","article-title":"Advances in targeted therapy of cholangiocarcinoma","volume":"56","author":"Li","year":"2024","journal-title":"Ann. Med"},{"issue":"12","key":"10.1016\/j.biopha.2025.118273_bib29","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat. Genet"},{"issue":"10","key":"10.1016\/j.biopha.2025.118273_bib30","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.biopha.2025.118273_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112641","article-title":"Timeline of FDA-approved targeted therapy for cholangiocarcinoma","volume":"14","author":"Cho","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.biopha.2025.118273_bib32","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006007","article-title":"Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling","volume":"7","author":"Oltvai","year":"2021","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"issue":"1","key":"10.1016\/j.biopha.2025.118273_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-021-01040-2","article-title":"FGFR-TKI resistance in cancer: current status and perspectives","volume":"14","author":"Yue","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118273_bib34","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.ajpath.2016.02.023","article-title":"Genomic and epigenomic alterations in cancer","volume":"186","author":"Chakravarthi","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"24","key":"10.1016\/j.biopha.2025.118273_bib35","doi-asserted-by":"crossref","first-page":"11157","DOI":"10.1111\/jcmm.17037","article-title":"MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM\/ATR and PI3K\/AKT pathways","volume":"25","author":"Zhou","year":"2021","journal-title":"J. Cell Mol. Med."},{"issue":"17","key":"10.1016\/j.biopha.2025.118273_bib36","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.3390\/cancers13174405","article-title":"Niraparib suppresses cholangiocarcinoma tumor growth by inducing oxidative and replication stress","volume":"13","author":"Bezrookove","year":"2021","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/j.biopha.2025.118273_bib37","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.biopha.2025.118273_bib38","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118273_bib39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/1078-0432.CCR-22-2551","article-title":"Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation","volume":"29","author":"Serra-Camprubi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118273_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard","year":"2015","journal-title":"Biomark. Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.118273_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188597","article-title":"Inhibiting homologous recombination by targeting RAD51 protein","volume":"1876","author":"Demeyer","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118273_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.101084","article-title":"ROS and the DNA damage response in cancer","volume":"25","author":"Srinivas","year":"2019","journal-title":"Redox Biol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:49:44Z","timestamp":1762310984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225004676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":42,"alternative-id":["S0753332225004676"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118273","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic suppression of cholangiocarcinoma cells via DNA damage response and cell cycle arrest by dual targeting PARP and ATM in DNA damage repair pathway","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118273"}}